Saphnelo

Chemical Nameanifrolumab-fnia
Dosage FormInjection (intravenous; 150 mg/mL)
Drug ClassReceptor antagonists
SystemImmune
CompanyAstraZeneca
Approval Year2021

Indication

  • For the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Saphnelo (anifrolumab-fnia) Prescribing Information.2021AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Assessment report: Saphnelo. 2022EMA